BARHEMSYS Drug Patent Profile
✉ Email this page to a colleague
When do Barhemsys patents expire, and when can generic versions of Barhemsys launch?
Barhemsys is a drug marketed by Acacia and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-eight patent family members in twenty-seven countries.
The generic ingredient in BARHEMSYS is amisulpride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amisulpride profile page.
DrugPatentWatch® Generic Entry Outlook for Barhemsys
Barhemsys was eligible for patent challenges on February 26, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 26, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BARHEMSYS?
- What are the global sales for BARHEMSYS?
- What is Average Wholesale Price for BARHEMSYS?
Summary for BARHEMSYS
| International Patents: | 68 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 141 |
| Patent Applications: | 4,249 |
| Drug Prices: | Drug price information for BARHEMSYS |
| What excipients (inactive ingredients) are in BARHEMSYS? | BARHEMSYS excipients list |
| DailyMed Link: | BARHEMSYS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BARHEMSYS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for BARHEMSYS
| Drug Class | Dopamine-2 Receptor Antagonist |
| Mechanism of Action | Dopamine D2 Antagonists |
US Patents and Regulatory Information for BARHEMSYS
BARHEMSYS is protected by nine US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of BARHEMSYS is ⤷ Sign Up.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting BARHEMSYS
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Rescue treatment of post operative nausea and vomiting
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
Use of amisulpride as an anti-emetic
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
FDA Regulatory Exclusivity protecting BARHEMSYS
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acacia | BARHEMSYS | amisulpride | SOLUTION;INTRAVENOUS | 209510-001 | Feb 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Acacia | BARHEMSYS | amisulpride | SOLUTION;INTRAVENOUS | 209510-001 | Feb 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Acacia | BARHEMSYS | amisulpride | SOLUTION;INTRAVENOUS | 209510-002 | Sep 1, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Acacia | BARHEMSYS | amisulpride | SOLUTION;INTRAVENOUS | 209510-002 | Sep 1, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Acacia | BARHEMSYS | amisulpride | SOLUTION;INTRAVENOUS | 209510-002 | Sep 1, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acacia | BARHEMSYS | amisulpride | SOLUTION;INTRAVENOUS | 209510-002 | Sep 1, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BARHEMSYS
See the table below for patents covering BARHEMSYS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20190111993 | 수술 후 오심 및 구토의 구제 치료 | ⤷ Sign Up |
| Cyprus | 1120170 | ⤷ Sign Up | |
| Poland | 2567690 | ⤷ Sign Up | |
| South Korea | 20130045241 | THE USE OF AMISULPRIDE AS AN ANTI-EMETIC | ⤷ Sign Up |
| United Kingdom | 201702250 | ⤷ Sign Up | |
| Japan | 7333269 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
